ArticleClinical rheumatology2013
Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities.
Article in Clinical rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Calprotectin, an available prognostic biomarker in systemic sclerosis: a systematic review.Clinical rheumatology · 2021Pooled it
- N-Formyl Methionine Peptide-Mediated Neutrophil Activation in Systemic Sclerosis.Frontiers in immunology · 2021Trial
- Serum Calprotectin as a Novel Biomarker of Disease Severity and Activity in Systemic Sclerosis Patients.International journal of molecular sciences · 2025Article
- Advances in S100 protein family for gynecological malignancies.Discover oncology · 2025Review
- Characteristics and multi-omics analysis of spontaneous spondyloarthritis in non-human primates: Case report.Heliyon · 2025Article
- The RAGE Pathway in Skin Pathology Development: A Comprehensive Review of Its Role and Therapeutic Potential.International journal of molecular sciences · 2024Review
- Nanoparticle-neutrophils interactions for autoimmune regulation.Advanced drug delivery reviews · 2024Review
- Efferocytosis dysfunction in CXCL4-induced M4 macrophages: phenotypic insights in systemic sclerosisFrontiers in immunology · 2024Article
- S100 calcium-binding protein A9 promotes skin regeneration through toll-like receptor 4 during tissue expansion.Burns & trauma · 2023Article
- Epiregulin is a dendritic cell-derived EGFR ligand that maintains skin and lung fibrosis.Science immunology · 2022Article
- Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.Arthritis research & therapy · 2022Article
- Autologous hematopoietic stem cell transplantation promotes connective tissue remodeling in systemic sclerosis patients.Arthritis research & therapy · 2022Article
- From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis.Frontiers in immunology · 2022Review
- An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod.Arthritis research & therapy · 2021Article
- Calprotectin in Lung Diseases.International journal of molecular sciences · 2021Review
- Role of Alarmins in the Pathogenesis of Systemic Sclerosis.International journal of molecular sciences · 2020Review
- S100 proteins in rheumatic diseases.Nature reviews. Rheumatology · 2018Review
- S100A8/A9 promotes parenchymal damage and renal fibrosis in obstructive nephropathy.Clinical and experimental immunology · 2018Article
- S100A9 aggravates bleomycin-induced dermal fibrosis in mice via activation of ERK1/2 MAPK and NF-κB pathways.Iranian journal of basic medical sciences · 2018Article
- Biomarkers in connective tissue diseases.The Journal of allergy and clinical immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
S100A8 and S100A9 play important roles in immune and inflammatory disorders. The role of the two proteins in systemic sclerosis (SSc) remains unknown. Fifty-seven diffuse cutaneous SSc (dcSSc) patients, 31 limited cutaneous SSc (lcSSc) patients were recruited in the present study. The expression of S100A8 and S100A9 in plasma was measured using an enzyme-linked immunosorbent assay and the mRNA levels in peripheral blood were assessed using reverse transcriptase quantitative PCR. The expression and distribution of S100A8, S100A9, and receptor for advanced glycation end products (RAGE), in skin tissues was analyzed by immunohistochemistry. The plasma concentrations of S100A8 and S100A9 were significantly higher in dcSSc patients than in normal controls and lcSSc patients. Both S100A8 and S100A9 levels were significantly increased in dcSSc patients with lung or kidney involvement. Increased plasma levels of S100A8 and S100A9 in dcSSc patients were associated with several autoantibodies. Transcription levels of S100A8 and S100A9 in peripheral blood were found elevated in both dcSSc and lcSSc patients than normal controls. Immunohistochemistry demonstrated higher S100A8 and S100A9 expression in sclerotic skin than in normal skin. The number of S100A8, S100A9, or RAGE positive fibroblasts was also significantly increased. Highly elevated expression of both S100A8 and S100A9 was found in dcSSc patients. There was close correlation with disease severity and serological abnormalities, suggesting that the two proteins may play important roles in the development of systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.